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ABSTRACT
In-vitro MICs and minimum bactericidal concentrations (MBCs) of daptomycin, linezolid, tigecycline,
vancomycin and teicoplanin against Gram-positive bacteria were determined using the broth
microdilution method for ten blood isolates each of methicillin-susceptible Staphylococcus aureus
(MSSA), methicillin-resistant S. aureus (MRSA), including two vancomycin-intermediate S. aureus
(VISA), vancomycin-resistant Enterococcus faecium and Enterococcus faecalis. One strain of VISA was
tested in a time-kill synergism assay of daptomycin combined with oxacillin, imipenem, rifampicin and
isepamicin. Daptomycin showed excellent in-vitro bactericidal activity against all the isolates tested,
with no tolerance or synergism effects when combined with other agents, except with rifampicin against
VISA. Vancomycin had better bactericidal activity against MRSA and MSSA than did teicoplanin.
Linezolid had the poorest bactericidal activity against the isolates tested, with 100% tolerance by the
MSSA and VRE isolates, and 80% tolerance by the MRSA isolates. Tolerance towards tigecycline was
exhibited by 40% of the MRSA isolates, 100% of the MSSA and vancomycin-resistant E. faecalis isolates,
and 90% of the vancomycin-resistant E. faecium isolates.
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INTRODUCTION
The unsatisfactory response to vancomycin treat-
ment associated with vancomycin-tolerant or
vancomycin-intermediate Staphylococcus aureus
(VISA) and vancomycin-resistant S. aureus in
cases of bacteraemia and endocarditis caused by
methicillin-resistant S. aureus (MRSA) necessitates
the development of new treatment options [1–3].
Rapidly increasing rates of MRSA in nosocomial
infections have been reported in Taiwan (from
26.3% in 1986 to 77% in 2001), with the emer-
gence of vancomycin-heteroresistant S. aureus
since 2000 [2,4,5]. A high rate of non-susceptibility
to quinupristin–dalfopristin has been revealed
among MRSA (31%) and vancomycin-resistant
Enterococcus faecium (66%) isolates, despite the
unavailability of this agent in Taiwan [6], and a
high frequency of linezolid-associated thrombo-
cytopenia and anaemia has been reported among
patients with renal insufficiency and end-stage
renal disease, associated with a high incidence of
MRSA bacteraemia [7,8]. These findings illustrate
the urgent need in Taiwan for alternative treat-
ments with activity against these pathogens.
Daptomycin is a cyclic lipopeptide antibiotic
with rapid bactericidal activity against vancomy-
cin-resistant E. faecium and Enterococcus faecalis
(VRE), MRSA, vancomycin-heteroresistant S. aureus
and VISA because of its calcium-dependent alter-
ation of the bacterial membrane potential [9].
Reduced susceptibility to daptomycin in S. aureus
has been reported in association with an increased
thickness of the cell wall [10]. Synergism between
daptomycin and other antibiotics, including
b-lactams and aminoglycosides, has been
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reported, but data concerning the efficacy of
combinations with other antibiotics remain scarce
[11,12].
Accordingly, the aim of the present study was
to determine the in-vitro bactericidal activity of
daptomycin, linezolid, tigecycline, vancomycin
and teicoplanin against blood isolates of methi-
cillin-susceptible S. aureus (MSSA), MRSA
(including VISA) and VRE. Time-kill experiments
involving combinations of daptomycin with oxa-
cillin, imipenem, rifampicin and isepamicin were
performed with one VISA strain.
MATERIALS AND METHODS
Bacterial isolates
Ten isolates each of non-duplicate blood isolates of MSSA,
MRSA (including two VISA isolates [5]), vancomycin-resistant
E. faecium and vancomycin-resistant E. faecalis were selected
from among isolates collected during 2000–2005. The vanco-
mycin MICs for the two VISA isolates were 6 mg ⁄L according
to Etests (AB Biodisk, Solna, Sweden) performed using the
high inoculum (2 · McFarland standard) method [5]. Eight of
ten MRSA isolates had oxacillin MICs >28 mg ⁄L (range 32 -
>128 mg ⁄L). All except one of the 20 VRE isolates had
vancomycin MICs >128 mg ⁄L (range 64 - >128 mg ⁄L), and
all VRE isolates had teicoplanin MICs >64 mg ⁄L (all expressed
the VanA phenotype). The imipenem, rifampicin and isep-
amicin MICs for the VISA isolate used in the time-kill
experiment were 16 mg ⁄L, >128 mg ⁄L and 32 mg ⁄L, respec-
tively. The isolates were stored at )70C in trypticase soy broth
(BBL Microbiology Systems, Cockeysville, MD, USA) supple-
mented with glycerol 15% v ⁄v. S. aureus ATCC 29213,
E. faecium ATCC 19434 and E. faecalis ATCC 29212 were
included as control strains.
Antimicrobial agents
The following antimicrobial agents were provided by their
manufacturers for use in this study: vancomycin and rifam-
picin (Sigma, St Louis, MO, USA); teicoplanin, (Aventis
Pharma, Romainville, France); linezolid (Pharmacia, Kalama-
zoo, MI, USA); tigecycline (Wyeth-Ayerst, Pearl River, NY,
USA); and daptomycin (Cubist Pharmaceuticals, Lexington,
MA, USA). The antimicrobial agents used in combination with
daptomycin for synergism evaluation against the VISA isolate
were rifampicin, isepamicin (Schering-Plough, Osaka, Japan),
imipenem–cilastatin (Merck Sharp & Dohme, West Point, PA,
USA) and oxacillin (Bristol-Myers Squibb, Princeton, NJ, USA).
Susceptibility testing
MICs and minimum bactericidal concentrations (MBCs) were
determined according to CLSI guidelines using the broth
microdilution method with an initial inoculum of 5 · 105 CFU ⁄
mL [13]. When testing daptomycin MICs and MBCs, the
medium used was Mueller–Hinton broth containing physio-
logical levels of calcium (50 mg ⁄L) [14]. Susceptibility to
glycopeptides, linezolid and daptomycin was determined
according to CLSI guidelines [13]. Rates of susceptibility to
tigecycline were determined on the basis of the recommended
breakpoints for staphylococci (£0.5 mg ⁄L) and enterococci
(£0.25 mg ⁄L) [15]. Tolerance was defined as an MBC ⁄MIC ratio
of ‡32 [16].
Time-kill studies
Time-kill bactericidal activity was determined using a starting
inoculum of 5 · 106 CFU ⁄mL as described previously [17].
Daptomycin concentrations of 4 · MIC, 2 · MIC, 1 · MIC,
0.5 · MIC and 0.25 · MIC for each isolate were analysed. The
MICs of oxacillin and rifampicin for the two VISA isolates
were both >128 mg ⁄L, so an initial drug concentration
of 128 mg ⁄L was chosen when testing these two agents
in combination with daptomycin. A physiological level of
calcium (50 mg ⁄L) was added to Mueller–Hinton broth when
testing daptomycin alone and in synergy time-kill assays.
Viable counts of dilutions of cultures containing antibiotics
were performed at 0, 1, 2, 4, 8 and 24 h. Plates yielding 30–300
bacterial colonies were counted. Each study was performed in
duplicate with appropriate growth controls, with the results
presented as an average value. Bactericidal activity was
defined as a ‡3 log10 decrease in the bacterial count at 8 and
24 h as compared with the count at 0 h. Synergy was defined
as a ‡2 log10 reduction in CFU with the combination as
compared with the single more active agent at 8 and 24 h.
Additivity was defined as a CFU decrease of 1–2 log10, and
indifference as an increase or decrease within 1 log10 of growth
at 8 and 24 h. Antagonism was defined as an increase in CFU
of ‡2 log10 after incubation with the combination, as compared
with the single more active agent at 24 h.
RESULTS
Antimicrobial susceptibility
The in-vitro activity of vancomycin, teicoplanin,
linezolid, tigecycline and daptomycin against
MSSA, MRSA (including VISA) and VRE is
summarised in Table 1. The MICs and MBCs of
control strains were within the expected ranges
[13]. Tigecycline had the lowest MICs among the
antibiotics tested against MSSA, MRSA and VRE
isolates, followed by daptomycin (Table 1). All of
the isolates were susceptible to daptomycin,
linezolid and tigecycline.
Tolerance
Tolerance to teicoplanin among MSSA and MRSA
isolates was more common than tolerance to
vancomycin (MSSA, 90% and 20%, and MRSA,
90% and 10%, respectively). Tolerance to tigecy-
cline was noted for 40% of MRSA, 100% of MSSA
and vancomycin-resistant E. faecalis, and 90% of
vancomycin-resistant E. faecium isolates. For
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linezolid, tolerance was exhibited by 100% of
MSSA and VRE isolates, and 80% of MRSA
isolates. No daptomycin tolerance was observed
for any of the isolates studied.
Time-kill studies
Daptomycin showed dose-dependent bactericidal
activity against MSSA, VISA and VRE in time-kill
experiments (Fig. 1). Bactericidal activity was
observed after 8 h for MSSA at ‡1 · MIC, for
VISA at ‡2 · MIC, for E. faecalis at ‡1 · MIC, and
for E. faecium at ‡4 · MIC. At 24 h, regrowth was
observed for E. faecalis at 1 · MIC, and for VISA
at 1 · MIC and 2 · MIC. For all isolates, there
was little difference at all time points between the
growth of the isolate at 0.25 · MIC and the
control. Bactericidal synergism was observed at
0.5 · MIC (5.42 log10 reduction at both 8 and
24 h) and 1 · MIC (5.26 log10 reduction at both 8
and 24 h) for daptomycin combined with oxacillin
(Fig. 2a). Synergism was also observed at
0.25 · MIC (3.05 log10 and 5.41 log10 reduction
at 8 and 24 h, respectively), at 0.5 · MIC
(3.64 log10 and 5.34 log10 reduction at 8 and
24 h, respectively) and at 1 · MIC (5.45 log10
reduction at both 8 and 24 h) for daptomycin
combined with imipenem (Fig. 2b). The combina-
tion of daptomycin and isepamicin showed syn-
ergism at 1 · MIC (5.26 log10 reduction at both 8
and 24 h) and at 0.5 · MIC (2.14 log10 reduction
at 8 h), but indifference at 0.25 · MIC. Regrowth
was observed after 24 h at 0.5 · MIC, but with
retained synergism (Fig. 2d). Daptomycin com-
bined with rifampicin demonstrated indifference
at 0.25 · MIC and early additivity at 0.5 · MIC
(8 h); however, antagonism was noted for the
combination of daptomycin plus rifampicin at
24 h (Fig. 2c).
DISCUSSION
Bactericidal activity appears to be necessary for
clinical efficacy in certain circumstances, e.g.,
endocarditis, meningitis, osteomyelitis and severe
infections involving neutropenic patients [18].
Vancomycin remains the treatment of choice for
severe MRSA infection, but its efficacy is inferior
to that of anti-staphylococcal penicillins against
MSSA [19]. In the present study, daptomycin had
the most potent in-vitro bactericidal activity
among the agents studied, with rapid bactericidal
activity against MSSA, VISA and VRE. A recent
study revealed that daptomycin showed
non-inferiority, as compared with the standard
regimens, for treating both MSSA and MRSA
bacteraemia and right-sided endocarditis [20].
Further studies are required to evaluate its clinical
efficacy against VISA.
An increase in vancomycin MIC, even within
the susceptible range, has raised the risk of
treatment failure in cases of MRSA bacteraemia
[21]. Tolerance to antibiotics could increase bac-
terial survival and regrowth after antibiotic
removal without altering the MIC. This phenom-
enon may provide a degree of antibiotic resistance
Table 1. In-vitro activity of daptomycin, vancomycin, teicoplanin, linezolid and tigecycline against 40 isolates of Gram-
positive bacteria
Bacteria
No. of
isolates
Antimicrobial
agent
MIC (mg ⁄L) MBC (mg ⁄L)
No. (%) of isolates
with toleranceaRange 50% 90% Range 50% 90%
MSSA 10 Daptomycin 0.25–1 0.25 0.5 0.25–4 0.5 2 0
Linezolid 1 1 1 ‡32 ‡32 ‡32 10 (100)
Tigecycline 0.12–0.25 0.12 0.12 ‡4–‡8 4 ‡8 10 (100)
Vancomycin 0.5–2 1 1 16–‡64 4 ‡64 2 (20)
Teicoplanin 0.5–4 0.5 1 8–‡128 ‡16 ‡32 9 (90)
MRSAb 10 Daptomycin 0.25–1 0.25 1 0.25–2 0.25 2 0
Linezolid 1–2 1 2 8–‡64 64 ‡64 8 (80)
Tigecycline 0.12–1 0.12 1 1–‡8 2 ‡4 4 (40)
Vancomycin 0.5–4 1 4 4–‡128 8 ‡128 1 (10)
Teicoplanin 0.5–8 1 4 8–‡256 ‡32 ‡128 9 (90)
VRE
(Enterococcus faecalis)
10 Daptomycin 1–2 1 2 4–8 8 8 0
Linezolid 1–2 2 2 ‡32–‡64 ‡64 ‡64 10 (100)
Tigecycline 0.12–0.25 0.12 0.25 ‡4–‡8 ‡8 ‡8 10 (100)
VRE
(Enterococcus faecium)
10 Daptomycin 1–4 2 4 1–8 4 8 0
Linezolid 1–2 2 2 ‡32–‡64 ‡64 ‡64 10 (100)
Tigecycline 0.06–0.12 0.06 0.06 0.5–‡4 ‡2 ‡2 9 (90)
aTolerance was defined as MBC ⁄MIC ‡32.
bTwo isolates of vancomycin-intermediate Staphylococcus aureus were included.
MBC, minimum bactericidal concentration; MSSA, methicillin-susceptible Staphylococcus aureus; MRSA, methicillin-resistant S. aureus; VRE, vancomycin-resistant enterococci.
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Fig. 1. Time-kill curves for (a) methicillin-susceptible Staphylococcus aureus, (b) methicillin-resistant vancomycin-interme-
diate S. aureus (vancomycin MIC 6 mg ⁄L), (c) vancomycin-resistant Enterococcus faecalis, and (d) vancomycin-resistant
Enterococcus faecium.
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against methicillin-resistant vancomycin-intermediate Staphylococcus aureus (vancomycin MIC 6 mg ⁄L).
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and increase the difficulty of treating infections,
e.g., endocarditis, that require effective bacterici-
dal action. Indeed, it has been suggested that
tolerance of MRSA to vancomycin should be
evaluated to assess the risk of clinical failure
during treatment [2]. Vancomycin tolerance has
been observed previously in £15.2% of wild-type
MRSA and 73.95% of vancomycin-heteroresistant
S. aureus isolates [2]. In the present study, 90% of
both MSSA and MRSA isolates were more sus-
ceptible to teicoplanin than to vancomycin (20%
and 10%, respectively), which is a finding similar
to that reported previously [22]. It is not surpris-
ing that a high proportion of MSSA, MRSA and
VRE isolates had an MBC ⁄MIC ratio of ‡32 for
linezolid and tigecycline, because of the bacterio-
static characteristics of these agents.
It is interesting to consider the implications of
regrowth in the presence of daptomycin at
1 · MIC for the VISA and VRE isolates in the
present study, which has also been noted previ-
ously [23]. This phenomenon disappeared after
increasing the daptomycin concentration to
4 · MIC for VISA and 2 · MIC for VRE, thereby
further illustrating the concentration-dependent
killing effecct of daptomycin [23,24]. The reasons
why daptomycin showed lower efficacy against
E. faecium when compared with the other isolates
(at 4 · MIC) in the present study remain unclear.
The inferior activity of daptomycin against E. fae-
cium, as compared with E. faecalis and MRSA
(including vancomycin-intermediate isolates),
might partly explain this phenomenon [23,25].
The daptomycin MIC for the VISA isolate studied
was 1 mg ⁄L, which is at the upper limit of the
CLSI breakpoint [13]. As the trough free drug
concentration may fall below the MIC (c. 0.6 mg ⁄L)
[12], caution is required when treating pathogens
with relatively high daptomycin MICs.
Daptomycin showed bactericidal synergy at
24 h when combined with oxacillin, imipenem
and isepamicin. Previous studies have reported
synergism between daptomycin and b-lactams,
despite the high MICs of b-lactams for MRSA and
VRE isolates [11,12,26]. In the present study,
daptomycin combined with imipenem showed
greater in-vitro synergy than when combined
with oxacillin and isepamicin, and maintained a
bactericidal effect against VISA, even at
0.25 · MIC. A serum concentration of
61.2 ± 9.8 mg ⁄L was clinically achievable 30 min
after an infusion of 1 g imipenem plus 1 g
cilastatin [27]. More data are required concerning
the efficacy of the combination of daptomycin and
imipinem against S. aureus isolates with a higher
daptomycin MIC.
The reasons for the difference in effects seen
when combining rifampicin with daptomycin
against the VISA isolate in the present study
remain to be clarified. A previous study found
that daptomycin combined with rifampicin had an
indifferent effect against 82% of Gram-positive
isolates studied [11], and no synergism was
observed between daptomycin and rifampicin for
rifampicin-susceptible or -resistant MRSA [12].
However, additivity was reported against two,
and synergy against one, of the three VISA isolates
for which no antagonism was detected [28]. The
isolate that showed synergy was susceptible to
rifampicin, whereas the VISA isolate in the present
study was resistant. Furthermore, the rifampicin
concentration used in the present study was higher
than that used previously (128 mg ⁄L and
0.004 mg ⁄L, respectively). The extent to which
the rifampicin concentration, or VISA susceptibil-
ity to rifampicin, affects the response to daptomy-
cin plus rifampicin remains to be clarified.
In conclusion, this study showed that dapto-
mycin had the most potent in-vitro bactericidal
activity against the MSSA, MRSA (including
VISA) and VRE isolates tested. Daptomycin plus
imipinem–cilastatin had the most effective
in-vitro synergy against a VISA isolate.
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